The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Open accessAbstract
BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. METHODS: We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vemurafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival. The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point. RESULTS: A total of 132 patients had a median follow-up of 12.9 months (range, 0.6 to 20.1). The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Primary progression was observed in only 14% of patients. Some patients had a response after receiving vemurafenib for more than 6 months. The median overall survival was 15.9 months (95% CI, 11.6 to 18.3). The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia. Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients. CONCLUSIONS: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma. In this study with a long follow-up, the median overall survival was approximately 16 months. (Funded by Hoffmann-La Roche; ClinicalTrials.gov number, NCT00949702.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, BRAF inhibitors led to a monotherapy response rate of >50% in BRAFV600E melanoma and ~30% in BRAFV600E NSCLC, but only ~5% in BRAFV600E colorectal cancer, likely due to the variable robustness of adaptive feedback networks in each tumor type (45–49).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043
Cited by
Sorted by citations
Items 801–900 of 1,003
Cutaneous toxicities of new treatments for melanoma
Boada, A., Carrera, C., Segura, S., Collgros, H., Pasquali, P., Bodet, D., Puig, S., & Malvehy, J. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1891-7 · Cited by 33
Garbe, C., Abusaif, S., & Eigentler, T. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_13 · Cited by 33
Profile of vemurafenib‐induced severe skin toxicities
Peuvrel, L., Quereux, G., Saint-Jean, M., Brocard, A., Nguyen, J., Khammari, A., Knol, A., Varey, É., & Dréno, B. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13443 · Cited by 32
Mattingly, R. R. (2013) · ISRN Oncology · doi:10.1155/2013/536529 · Cited by 33
New therapeutic strategies for BRAF mutant colorectal cancers.
Corcoran, R. B. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.076 · Cited by 32
Gupta, S., & Tsao, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-35153-7_31 · Cited by 32
MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor
Aida, S., Sonobe, Y., Tanimura, H., Oikawa, N., Yuhki, M., Sakamoto, H., & Mizuno, T. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.008 · Cited by 33
RTL1 promotes melanoma proliferation by regulating Wnt/β-catenin signalling
Fan, G., Ye, D., Zhu, S., Xi, J., Guo, X., Qiao, J., Wu, Y., Jia, W., Wang, G., Fan, G.-H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22523 · Cited by 33
Yu, H., Ma, M., Yan, J., Xu, L., Yu, J., Dai, J., Xu, T., Tang, H., Wu, X., Li, S., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1344-z · Cited by 33
Meng, Y., Hertel, N., Ellis, J., Morais, E., Johnson, H., Philips, Z., Roskell, N., Walker, A., & Lee, D. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-018-0964-4 · Cited by 32
Chk1 inhibition as a novel therapeutic strategy in melanoma
Hwang, B., Adhikary, G., Eckert, R. L., & Lu, A.-L. (2018) · Oncotarget · doi:10.18632/oncotarget.25765 · Cited by 32
Update on systemic therapy for colorectal cancer: biologics take sides
Gbolahan, O. B., & O’Neil, B. H. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.01.12 · Cited by 33
RAS pathway regulation in melanoma
Mahi, A. A., & Ablain, J. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049229 · Cited by 33
BRAF Inhibitors in Non-Small Cell Lung Cancer
Sforza, V., Palumbo, G., Cascetta, P., Carillio, G., Manzo, A., Montanino, A., Sandomenico, C., Costanzo, R., Esposito, G., Laudato, F., et al. (2022) · Cancers · doi:10.3390/cancers14194863 · Cited by 34
Receptor tyrosine kinases in cancer escape from BRAF inhibitors
Lo, R. S. (2012) · Cell Research · doi:10.1038/cr.2012.78 · Cited by 32
Dickson, M. A., Gordon, M. S., Edelman, G. M., Bendell, J. C., Kudchadkar, R. R., LoRusso, P. M., Johnston, S. H., Clary, D. O., & Schwartz, G. K. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0191-5 · Cited by 32
Long-term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma
Hu, Y., Kim, H., Blackwell, C. M., & Slingluff, C. L. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001419 · Cited by 32
BRAF Inhibitor–Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma
Garrido, M. C., Gutierrez, C., Riveiro‐Falkenbach, E., Ortiz-Romero, P. L., & Rodríguez‐Peralto, J. L. (2015) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000281 · Cited by 32
The soy-derived peptide Lunasin inhibits invasive potential of melanoma initiating cells
Shidal, C., Inaba, J.-I., Yaddanapudi, K., & Davis, K. (2017) · Oncotarget · doi:10.18632/oncotarget.16066 · Cited by 32
Kim, S. T., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Kang, W. K., & Lim, H. Y. (2017) · BMC Cancer · doi:10.1186/s12885-017-3196-6 · Cited by 34
AACR Cancer Progress Report 2012
Cantley, L. C., Dalton, W. S., DuBois, R. N., Finn, O. J., Futreal, P. A., Golub, T. R., Hait, W. N., Lozano, G., Maris, J. M., Nelson, W. G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2891 · Cited by 32
Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action
Mandalà, M., Massi, D., & GIORGI, V. D. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.002 · Cited by 31
Hoogstraat, M., Hooijdonk, C. G. G., Ubink, I., Besselink, N. J. M., Pieterse, M., Veldhuis, W. B., van Stralen, M., Meijer, E. F. J., Willems, S. M., Hadders, M. A., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12347 · Cited by 31
Mangana, J., Cheng, P. F., Schindler, K., Weide, B., Held, U., Frauchiger, A. L., Romano, E., Kähler, K. C., Rozati, S., Rechsteiner, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139438 · Cited by 31
Current Systemic Therapies for Melanoma
Palathinkal, D. M., Sharma, T. R., Koon, H. B., & Bordeaux, J. S. (2014) · Dermatologic Surgery · doi:10.1097/01.dss.0000452626.09513.55 · Cited by 31
Cutaneous manifestations of nontargeted and targeted chemotherapies
Shi, V. J., Levy, L., & Choi, J. N. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.02.018 · Cited by 31
Teh, J. L. F., Purwin, T. J., Greenawalt, E. J., Chervoneva, I., Goldberg, A. F., Davies, M. A., & Aplin, A. E. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3384 · Cited by 31
Interaction of molecular alterations with immune response in melanoma
Sloane, R. A. S., Gopalakrishnan, V., Reddy, S. M., Zhang, X., Reuben, A., & Wargo, J. A. (2017) · Cancer · doi:10.1002/cncr.30681 · Cited by 31
Hannan, E., O’Leary, D. P., MacNally, S. P., Kay, E. W., Farrell, M. A., Morris, P. G., Power, C. P., & Hill, A. D. K. (2017) · Medicine · doi:10.1097/md.0000000000008404 · Cited by 31
Purdie, K. J., Proby, C. M., Rizvi, H., Griffin, H. M., Doorbar, J., Sommerlad, M., Feltkamp, M. C. W., van der Meijden, E., Inman, G. J., South, A. P., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01806 · Cited by 31
Coding Molecular Determinants of Thyroid Cancer Development and Progression
Valvo, V., & Nucera, C. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.10.003 · Cited by 31
Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition
Zaoui, I. E., Bucher, M., Rimoldi, D., Nicolas, M., Kaya, G., Gobert, R. P., Bedoni, N., Schalenbourg, A., Ezziat, S., Zografos, L., et al. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-26508 · Cited by 31
From Tank to Treatment: Modeling Melanoma in Zebrafish
Frantz, W. T., & Ceol, C. J. (2020) · Cells · doi:10.3390/cells9051289 · Cited by 35
Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
Savoia, P., Zavattaro, E., & Cremona, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249730 · Cited by 31
Coventry, B. J., & Ashdown (2012) · Cancer Management and Research · doi:10.2147/cmar.s31887 · Cited by 31
Disruption of GRM 1‐mediated signalling using riluzole results in DNA damage in melanoma cells
Wall, B., Wangari‐Talbot, J., Shin, S., Schiff, D. S., Sierra, J., Yu, L. J., Khan, A. J., Haffty, B. G., Goydos, J. S., & Chen, S. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12207 · Cited by 31
Cohen, D. N., Lawson, S. K., Shaver, A. C., Du, L., Nguyen, H. P., He, Q., Johnson, D. B., Lumbang, W. A., Moody, B. R., Prescott, J. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2667 · Cited by 31
Self-citationThe anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth
Hanson, K., Robinson, S. D., Al‐Yousuf, K., Hendry, A. E., Sexton, D. W., Sherwood, V., & Wheeler, G. N. (2017) · Oncotarget · doi:10.18632/oncotarget.23378 · Cited by 34
A Nonquiescent “Idling” Population State in Drug-Treated, BRAF-Mutated Melanoma
Paudel, B. B., Harris, L. A., Hardeman, K. N., Abugable, A. A., Hayford, C. E., Tyson, D. R., & Quaranta, V. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.01.016 · Cited by 31
T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma
Barceló, C., Sisó, P., Maiques, Ó., García‐Mulero, S., Pamplona, R. S., Navaridas, R., Megino‐Luque, C., Felip, I., Urdanibia, I., Eritja, N., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.11.014 · Cited by 31
Functions of MAP3Ks in antiviral immunity
Guan, J., Fan, Y., Wang, S., & Zhou, F. (2023) · Immunologic Research · doi:10.1007/s12026-023-09401-4 · Cited by 30
High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?
Amin, A., & White, R. L. (2013) · PubMed · Cited by 30
Melanoma: oncogenic drivers and the immune system.
Karachaliou, N., Pilotto, S., Teixidó, C., Viteri, S., González‐Cao, M., Riso, A. A., Morales-Espinosa, D., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Santarpía, M., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.06 · Cited by 30
Systemic therapies for inflammatory eye disease: Past, Present and Future
Denniston, A. K., & Dick, A. D. (2013) · BMC Ophthalmology · doi:10.1186/1471-2415-13-18 · Cited by 30
Effets indésirables cutanés des inhibiteurs de BRAF : revue systématique
Sibaud, V., Lamant, L., Maisongrosse, V., & Delord, J. (2013) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2013.02.031 · Cited by 30
Posch, C., Weihsengruber, F., Bartsch, K., Feichtenschlager, V., Sanlorenzo, M., Vujic, I., Itzinger-Monshi, B., Ortiz‐Urda, S., & Rappersberger, K. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.62 · Cited by 30
Dillman, R. O., Cornforth, A. N., & Nistor, G. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.759556 · Cited by 30
MEK and RAF inhibitors for BRAF-mutated cancers
Belden, S. E., & Flaherty, K. T. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.11 · Cited by 30
Self-citationPenna, I., Molla, A., Grazia, G., Cleris, L., Nicolini, G., Perrone, F., Picciani, B., Vecchio, M. D., de Braud, F., Mortarini, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6600 · Cited by 30
Bonavida, B. (2018) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2018027212 · Cited by 30
Uitdehaag, J. C. M., Kooijman, J. J., de Roos, J. A. D. M., Prinsen, M. B. W., Dylus, J., Willemsen‐Seegers, N., Kawase, Y., Sawa, M., de Man, J., van Gerwen, S. J. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0877 · Cited by 30
Capatina, C. A.-M., Hinojosa‐Amaya, J. M., Poiană, C., & Fleseriu, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1802243 · Cited by 30
van Harten, A. M., & Brakenhoff, R. H. (2021) · Cancers · doi:10.3390/cancers13112774 · Cited by 33
Autophagy controls programmed death‑ligand 1 expression on cancer cells (Review)
Gao, L., & Chen, Y. (2021) · Biomedical Reports · doi:10.3892/br.2021.1460 · Cited by 32
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors
Falini, B., Carolis, L. D., & Tiacci, E. (2022) · Blood · doi:10.1182/blood.2021013502 · Cited by 31
New Strategies in Melanoma: Entering the Era of Combinatorial Therapy
Sullivan, R. J., & Flaherty, K. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1650 · Cited by 30
Self-citationSevere cutaneous adverse reaction associated with vemurafenib: DRESS , AGEP or overlap reaction?
Gey, A., Milpied, B., Dutriaux, C., Mateus, C., Robert, C., Perro, G., Taı̈eb, A., Ezzedine, K., & Jouary, T. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12685 · Cited by 30
Apoptosis Induced by Ginkgo biloba (EGb761) in Melanoma Cells Is Mcl-1-Dependent
Wang, Y., Lv, J., Cheng, Y., Du, J., Chen, D., Li, C., & Zhang, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124812 · Cited by 30
KRAS, BRAF, and TP53 Deep Sequencing for Colorectal Carcinoma Patient Diagnostics
Rechsteiner, M., von Teichman, A., Rüschoff, J. H., Fankhauser, N., Pestalozzi, B. C., Schraml, P., Weber, A., Wild, P. J., Zimmermann, D. R., & Moch, H. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.02.001 · Cited by 30
Human Correlates of Provocative Questions in Pancreatic Pathology
McDonald, O. G., Maitra, A., & Hruban, R. H. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e318273f998 · Cited by 30
A new look at drugs targeting malignant melanoma—An application for mass spectrometry imaging
Sugihara, Y., Végvári, Á., Welinder, C., Jönsson, G. B., Ingvar, C., Lundgren, L., Olsson, H. L., Breslin, T., Wieslander, E., Laurell, T., et al. (2014) · PROTEOMICS · doi:10.1002/pmic.201300476 · Cited by 30
The role of high-throughput technologies in clinical cancer genomics
Idris, S. F., Ahmad, S. S., Scott, M. A., Vassiliou, G. S., & Hadfield, J. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.13.1 · Cited by 30
Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease
Brugière, C., Stefan, A., Morice, C., Cornet, É., Moreau, A., Allouche, S., & Verneuil, L. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13300 · Cited by 30
Lewis, K. D., Larkin, J., Ribas, A., Flaherty, K. T., McArthur, G. A., Ascierto, P. A., Dréno, B., Yan, Y., Wongchenko, M. J., Mckenna, E. F., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0546-y · Cited by 30
Self-citationTargeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma
LoRusso, P. M., Schalper, K. A., & Sosman, J. A. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12847 · Cited by 30
Self-citationAntitumor effect of pharmacologic ascorbate in the B16 murine melanoma model
Serrano, O. K., Parrow, N. L., Violet, P.-C., Yang, J., Zornjak, J., Basseville, A., & Levine, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.032 · Cited by 29
Xie, J., Liu, J., Zhao, M., Li, X., Wang, Y., Zhao, Y., Cao, H., Ji, M., Chen, M., & Hou, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043418 · Cited by 29
Wyluda, E., Cheng, J., Schell, T. D., Haley, J. S., Mallon, C. A., Neves, R. I., Robertson, G. P., Sivik, J. M., Mackley, H. B., Talamo, G., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1026507 · Cited by 29
Kudchadkar, R. R., Smalley, K. S. M., Glass, L. F., Trimble, J. S., & Sondak, V. K. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.013 · Cited by 29
New combinations and immunotherapies for melanoma: latest evidence and clinical utility
Menzies, A. M., & Long, G. V. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834013499637 · Cited by 29
Skin cancer in kidney transplant recipients
Ponticelli, C. E., Cucchiari, D., & Bencini, P. L. (2014) · Journal of Nephrology · doi:10.1007/s40620-014-0098-4 · Cited by 30
Patel, D., Gao, Y., Son, K., Siltanen, C. A., Neve, R. M., Ferrara, K. W., & Revzin, A. (2015) · Lab on a Chip · doi:10.1039/c5lc00948k · Cited by 29
Somatic DNA mutation analysis in targeted therapy of solid tumours.
Yu, B., O'Toole, S. A., & Trent, R. J. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.04.04 · Cited by 29
Parthenolide enhances dacarbazine activity against melanoma cells
Koprowska, K., Hartman, M. L., Sztiller-Sikorska, M., & Czyż, M. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283635a04 · Cited by 29
New treatment options in hairy cell leukemia with focus on BRAF inhibitors
Falini, B., & Tiacci, E. (2019) · Hematological Oncology · doi:10.1002/hon.2594 · Cited by 29
Loureiro, J. B., Raimundo, L., Calheiros, J., Carvalho, C. S. C., Barcherini, V., Lima, N. R., Gomes, C. M. F., Almeida, M. I., Alves, M. G., Costa, J. L., et al. (2021) · Cancers · doi:10.3390/cancers13071648 · Cited by 29
García-Rendueles, M. E. R., Krishnamoorthy, G. P., Saqcena, M., Acuña-Ruíz, A., Revilla, G., de Stanchina, E., Knauf, J. A., Lester, R., Xu, B., Ghossein, R. A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01676-9 · Cited by 29
Gupta, A., Kurzrock, R., & Adashek, J. J. (2023) · Cancers · doi:10.3390/cancers15051578 · Cited by 29
Leslie, C., Bowyer, S. E., White, A. C., Grieu‐Iacopetta, F., Trevenen, M., Iacopetta, B. J., Amanuel, B., & Millward, M. J. (2015) · Pathology · doi:10.1097/pat.0000000000000314 · Cited by 29
Mourah, S., Denis, M. G., Escande, F., Solassol, J., Merlin, J., Sabourin, J., Scoazec, J., Ouafik, L., Emile, J., Heller, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120232 · Cited by 30
Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma
Litvin, O., Schwartz, S., Wan, Z., Schild, T., Rocco, M., Oh, N. L., Chen, B.-J., Goddard, N. L., Pratilas, C. A., & Pe’er, D. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.030 · Cited by 29
Frauchiger, A. L., Mangana, J., Rechsteiner, M., Moch, H., Seifert, B., Braun, R. P., Dummer, R., & Goldinger, S. M. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14347 · Cited by 29
Zheng, G., Tsai, H. K., Tseng, L., Illei, P. B., Gocke, C. D., Eshleman, J. R., Netto, G. J., & Lin, M. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw043 · Cited by 29
Donson, A. M., Amani, V. M., Warner, E. A., Griesinger, A. M., Witt, D. A., Levy, J. M. M., Hoffman, L. M., Hankinson, T. C., Handler, M. H., Vibhakar, R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1185 · Cited by 29
Wheler, J. J., Yelensky, R., Falchook, G. S., Kim, K. B., Hwu, P., Tsimberidou, A. M., Stephens, P. J., Hong, D. S., Cronin, M. T., & Kurzrock, R. (2015) · BMC Cancer · doi:10.1186/s12885-015-1029-z · Cited by 28
Self-citationStadelmeyer, E., Heitzer, E., Resel, M., Cerroni, L., Wolf, P., & Dandachi, N. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.338 · Cited by 28
Johnson, A. S., Crandall, H., Dahlman, K. B., & Kelley, M. C. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2014.12.057 · Cited by 28
Sanmamed, M. F., Landazuri, S. F., Rodríguez, C., Lozano, M. D., Echeveste, J. I., Perez‐Gracia, J. L., Alegre, E., Carranza, O. E., Zubiri, L., Martín‐Algarra, S., et al. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.11.034 · Cited by 28
Erythema Nodosum–Like Panniculitis in Patients With Melanoma Treated With Vemurafenib
Sinha, R., Edmonds, K., Newton‐Bishop, J., Gore, M. E., Larkin, J., & Fearfield, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8307 · Cited by 28
Micel, L. N., Tentler, J. J., Tan, A. C., Selby, H. M., Brunkow, K. L., Robertson, K. M., Davis, S. L., Klauck, P. J., Pitts, T. M., Gangolli, E. A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1012 · Cited by 28
Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma
Mochizuki, H., & Breen, M. (2016) · Veterinary and Comparative Oncology · doi:10.1111/vco.12275 · Cited by 28
Nanomedicine as a potent strategy in melanoma tumor microenvironment
Pautu, V., Leonetti, D., Lepeltier, É., Clere, N., & Passirani, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.014 · Cited by 28
Grandal, M. M., Havrylov, S., Poulsen, T. T., Koefoed, K., Dahlman, A., Galler, G. R., Conrotto, P., Collins, S., Eriksen, K. W., Kaufman, D. W., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0374 · Cited by 28
RAGE Signaling in Melanoma Tumors
Olaoba, O. T., Kadasah, S. F., Vetter, S. W., & Leclerc, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238989 · Cited by 28
Green, J. S., Norris, D. A., & Wisell, J. A. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12279 · Cited by 28
Vemurafenib (RG67204, PLX4032): A Potent, Selective BRAF Kinase Inhibitor
Patrawala, S. A., & Puzanov, I. J. (2012) · Future Oncology · doi:10.2217/fon.12.31 · Cited by 28
Self-citationLv, X., Ren, Z., Zhou, B., Li, Q., Chu, M., Liu, D.-H., Mo, K., Zhang, L., Yao, X., & Cao, H. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.08.002 · Cited by 28
Valianatos, G., Valčíková, B., Growková, K., Verlande, A., Mlčochová, J., Radová, L., Štětková, M., Vyhnakova, M., Slabý, O., & Uldrijan, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185801 · Cited by 28
Degradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation
Li, Y., Wu, C., Shah, S. S., Chen, S., Wangpaichitr, M., Kuo, M. T., Feun, L. G., Han, X., Suarez, M., Prince, J. S., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12151 · Cited by 28
Khanna, G., Pathak, P., Suri, V. S., Sharma, M. C., Chaturvedi, S., Ahuja, A., Bhardwaj, M., Garg, A. K., Sarkar, C., & Sharma, R. K. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.03.019 · Cited by 28
Metadata
- Authors
- Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., Hersey, P., Kefford, R., Lawrence, D., Puzanov, I., Lewis, K. D., Amaravadi, R. K., Chmielowski, B., Lawrence, H. J., Shyr, Y., Ye, F., Li, J., Nolop, K. B., Lee, R. J., Joe, A. K., & Ribas, A.
- Affiliations
- Vanderbilt University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Abramson Cancer Center (US)
- University of Colorado Denver (US)
- New York University (US)
- Moffitt Cancer Center (US)
- Peter MacCallum Cancer Centre (AU)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- University of Newcastle Australia (AU)
- Melanoma Institute Australia (AU)
- Vanderbilt-Ingram Cancer Center (US)
- University of California, Los Angeles (US)
- Vanderbilt University Medical Center (US)
- Plexxikon (United States) (US)
- ORCID
- Sosman, Jeffrey A.
- Kim, Kevin B.
- Schuchter, Lynn
- Gonzalez, Rene
- Pavlick, Anna C.
- Weber, Jeffrey S.
- McArthur, Grant A.
- Hutson, Thomas E.
- Moschos, Stergios J.
- Flaherty, Keith T.
- Hersey, Peter
- Kefford, Richard
- Lawrence, Donald
- Puzanov, Igor
- Lewis, Karl D.
- Amaravadi, Ravi K.
- Chmielowski, Bartosz
- Shyr, Yu
- Ye, Fei
- Li, Jiang
- Lee, Richard J.
- Ribas, Antoni
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-02-23
- Volume
- 366
- Issue
- 8
- Pages
- 707-714
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3724515
- OpenAlex
- W2168143310
- Cited by
- 2,156
- References
- 36
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 56 · 2023: 85 · 2022: 113 · 2021: 88 · 2020: 110 · 2019: 109 · 2018: 132 · 2017: 171 · 2016: 198 · 2015: 258 · 2014: 318 · 2013: 306 · 2012: 160
- FWCI
- 133.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Figshare (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (K24CA097588, P30CA076292)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, metastatic melanoma, BRAF inhibitors, overall survival, overall response rate, duration of response, progression-free survival, cutaneous squamous cell carcinoma, keratoacanthoma, adverse events
- MeSH terms
- Vemurafenib, Adult, Aged, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Neoplasm Metastasis, Sulfonamides, Treatment Outcome, Disease Progression, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
